PTEN and VEGF: Possible predictors for sentinel lymph node micro-metastasis in breast cancer

Li, 1997, TEP1, encoded by a candidate tumor suppressor locus, is a novel protein tyrosine phosphatase regulated by transforming growth factor beta, Cancer Res, 57, 2124 Steck, 1997, Identification of a candidate tumour suppressor gene MMAC1, at chromosome 10q23.3 that is mutated in multiple advanced cancers, Nat Genet, 15, 356, 10.1038/ng0497-356 Liaw, 1997, Germline mutations of the PTEN gene in Cowden disease, an inherited breast and thyroid cancer syndrome, Nat Genet, 16, 64, 10.1038/ng0597-64 Freihoff, 1999, Exclusion of a major role for the PTEN tumour-suppressor gene in breast carcinomas, Br J Cancer, 79, 754, 10.1038/sj.bjc.6690121 Feilotter, 1999, Analysis of the 10q23 chromosomal region and the PTEN gene in human sporadic breast carcinoma, Br J Cancer, 79, 718, 10.1038/sj.bjc.6690115 Jiang, 2003, Expression and significance of PTEN, hypoxia-inducible factor-1 alpha in colorectal adenoma and adenocarcinoma, World J Gastroenterol, 9, 491, 10.3748/wjg.v9.i3.491 Keck, 1989, Vascular permeability factor, an endothelial cell mitogen related to PDGF, Science, 246, 1309, 10.1126/science.2479987 Leung, 1989, Vascular endothelial growth factor is a secreted angiogenic mitogen, Science, 246, 1306, 10.1126/science.2479986 Bosari, 1992, Microvessel quantitation and prognosis in invasive ductal carcinoma, Hum Pathol, 23, 755, 10.1016/0046-8177(92)90344-3 Pantel, 1999, Detection and clinical importance of micrometastatic disease, J Natl Cancer Inst, 91, 1113, 10.1093/jnci/91.13.1113 Hellman, 1997, Stopping metastases at their source, N Engl J Med, 337, 996, 10.1056/NEJM199710023371408 Sidransky, 1997, Nucleic acid-based methods for the detection of cancer, Science, 278, 1054, 10.1126/science.278.5340.1054 Solakoglu, 2002, Heterogeneous proliferative potential of occult metastatic cells in bone marrow of patients with solid epithelial tumors, Proc Natl Acad Sci U S A, 99, 2246, 10.1073/pnas.042372199 Klein, 2002, Genetic heterogeneity of single disseminated tumor cells in minimal residual cancer, Lancet, 360, 683, 10.1016/S0140-6736(02)09838-0 Schmidt-Kittler, 2003, From latent disseminated cells to overt metastasis: genetic analysis of systemic breast cancer progression, Proc Natl Acad Sci U S A, 100, 7737, 10.1073/pnas.1331931100 Hu, 2003, Immunomagnetic tumor cell enrichment is promising in detecting circulating breast cancer cells, Oncology, 64, 160, 10.1159/000067776 Zhu, 2005, Circulating tumor cells in patients with breast cancer: possible predictor of micro-metastasis in bone marrow but not in sentinel lymph nodes, Biomed Pharmacother, 59, s355, 10.1016/S0753-3322(05)80077-0 Perren, 1999, Immunohistochemical evidence of loss of PTEN expression in primary ductal adenocarcinomas of the breast, Am J Pathol, 155, 1253, 10.1016/S0002-9440(10)65227-3 Depowski, 2001, Loss of expression of the PTEN gene protein product is associated with poor outcome in breast cancer, Mod Pathol, 14, 672, 10.1038/modpathol.3880371 Maehama, 1998, The tumor suppressor, PTEN/MMAC1, dephosphorylates the lipid second messenger, phosphatidylinositol 3,4,5-trisphosphate, J Biol Chem, 273, 13375, 10.1074/jbc.273.22.13375 Downward, 1998, Mechanisms and consequences of activation of protein kinase B/Akt, Curr Opin Cell Biol, 10, 262, 10.1016/S0955-0674(98)80149-X Giri, 1999, Inactivation of the PTEN tumor suppressorgene is associated with increased angiogenesis in clinically localized prostate carcinoma, Hum Pathol, 30, 419, 10.1016/S0046-8177(99)90117-X Bose, 2002, Reduced expression of PTEN correlates with breast cancer progression, Hum Pathol, 33, 405, 10.1053/hupa.2002.124721